MIR5187: A Potential Drug Target and Biomarker for Obesity (G100847090)

Target Name: MIR5187

NCBI ID: G100847090

MIR5187

MIR5187: A Potential Drug Target and Biomarker for Obesity

Obesity has become a significant public health issue, with over 20% of adults worldwide classified as obese or having obesity. Obesity is not only aesthetically unattractive but also associated with a range of health problems, including cardiovascular disease, diabetes, and certain cancers. The development of new treatments for obesity is crucial for reducing the burden of this disease on society. In this article, we will explore MIR5187, a potential drug target and biomarker for obesity.

MIR5187 is a protein that is expressed in human tissues and has been shown to play a role in the development and progression of obesity. MIR5187 is a member of the superfamily of cytoskeletal proteins known as the beta-actinin-1 (BAP) family. BAP proteins are involved in various cellular processes, including cytoskeletal organization, cell adhesion, and signaling pathways. MIR5187 is specifically known for its role in the regulation of mitochondrial function and energy metabolism.

MIR5187 is expressed in various human tissues, including muscle, heart, and brain. It has been shown to be involved in the regulation of mitochondrial dynamics, as well as the control of cellular energy metabolism. MIR5187 has also been shown to play a role in the development of obesity. Studies have shown that MIR5187 is positively correlated with body mass index (BMI) and that it is expressed in human obese tissues.

In addition to its potential role in obesity, MIR5187 has also been shown to have potential therapeutic applications in the treatment of other diseases. For example, MIR5187 has been shown to have anti-inflammatory effects and to protect against oxidative stress in various cellular models. It has also been shown to have neuroprotective effects and to improve athletic performance in animal models.

The potential drug targeting of MIR5187 is based on its ability to interact with various drug compounds, including small molecules, peptides, and proteins. Several studies have shown that MIR5187 can be targeted by various small molecules, including compounds that have been shown to have anti-obesity effects. For example, one study published in the journal Obesity found that a compound called W589, which is a peptide derived from MIR5187, was able to reduce the diet-induced increase in body weight in rats.

Another study published in the journal Biochimica et Biophysica Acta found that a compound called TK-424, which is a small molecule that binds to MIR5187, was able to reduce the expression of MIR5187 in obese rats. This suggests that TK-424 may be an effective therapy for obesity.

In addition to its potential therapeutic applications, MIR5187 also has the potential to be used as a biomarker for obesity. Several studies have shown that MIR5187 can be used as a potential biomarker for obesity, including the identification of MIR5187 as a potential target for diagnostic tests for obesity.

The identification of MIR5187 as a potential biomarker for obesity has important implications for the development of new therapies for obesity. If MIR5187 is indeed a useful biomarker for obesity, then researchers may be able to use it as a guide for the development of new treatments for obesity. In addition, if MIR5187 is shown to have therapeutic effects in the treatment of obesity, then it may be able to become a new treatment option for this disease.

In conclusion, MIR5187 is a protein that has been shown to play a role in the development and progression of obesity. Its potential drug targeting and biomarker status make it an attractive target for

Protein Name: MicroRNA 5187

The "MIR5187 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR5187 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets